Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise
dc.contributor.author | Fransen, Jaap | en_US |
dc.contributor.author | Johnson, Sindhu R. | en_US |
dc.contributor.author | van den Hoogen, Frank | en_US |
dc.contributor.author | Baron, Murray | en_US |
dc.contributor.author | Allanore, Yannick | en_US |
dc.contributor.author | Carreira, Patricia E. | en_US |
dc.contributor.author | Czirják, László | en_US |
dc.contributor.author | Denton, Christopher P. | en_US |
dc.contributor.author | Distler, Oliver | en_US |
dc.contributor.author | Furst, Daniel E. | en_US |
dc.contributor.author | Gabrielli, Armando | en_US |
dc.contributor.author | Herrick, Ariane | en_US |
dc.contributor.author | Inanc, Murat | en_US |
dc.contributor.author | Kahaleh, Bashar | en_US |
dc.contributor.author | Kowal‐bielecka, Otylia | en_US |
dc.contributor.author | Medsger, Thomas A. | en_US |
dc.contributor.author | Mueller‐ladner, Ulf | en_US |
dc.contributor.author | Riemekasten, Gabriela | en_US |
dc.contributor.author | Sierakowski, Stanislaw | en_US |
dc.contributor.author | Valentini, Gabriele | en_US |
dc.contributor.author | Veale, Doug | en_US |
dc.contributor.author | Vonk, Madelon C. | en_US |
dc.contributor.author | Walker, Ulrich | en_US |
dc.contributor.author | Chung, Lorinda | en_US |
dc.contributor.author | Clements, Philip J. | en_US |
dc.contributor.author | Collier, David H. | en_US |
dc.contributor.author | Csuka, Mary E. | en_US |
dc.contributor.author | Jimenez, Sergio | en_US |
dc.contributor.author | Merkel, Peter A. | en_US |
dc.contributor.author | Seibold, James R. | en_US |
dc.contributor.author | Silver, Richard | en_US |
dc.contributor.author | Steen, Virginia | en_US |
dc.contributor.author | Tyndall, Alan | en_US |
dc.contributor.author | Matucci‐cerinic, Marco | en_US |
dc.contributor.author | Pope, Janet E. | en_US |
dc.contributor.author | Khanna, Dinesh | en_US |
dc.date.accessioned | 2012-03-16T15:57:49Z | |
dc.date.available | 2013-05-01T17:24:40Z | en_US |
dc.date.issued | 2012-03 | en_US |
dc.identifier.citation | Fransen, Jaap; Johnson, Sindhu R.; van den Hoogen, Frank; Baron, Murray; Allanore, Yannick; Carreira, Patricia E.; Czirják, László ; Denton, Christopher P.; Distler, Oliver; Furst, Daniel E.; Gabrielli, Armando; Herrick, Ariane; Inanc, Murat; Kahaleh, Bashar; Kowal‐bielecka, Otylia ; Medsger, Thomas A.; Mueller‐ladner, Ulf ; Riemekasten, Gabriela; Sierakowski, Stanislaw; Valentini, Gabriele; Veale, Doug; Vonk, Madelon C.; Walker, Ulrich; Chung, Lorinda; Clements, Philip J.; Collier, David H.; Csuka, Mary E.; Jimenez, Sergio; Merkel, Peter A.; Seibold, James R.; Silver, Richard; Steen, Virginia; Tyndall, Alan; Matucci‐cerinic, Marco ; Pope, Janet E.; Khanna, Dinesh (2012). "Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise." Arthritis Care & Research 64(3): 351-357. <http://hdl.handle.net/2027.42/90249> | en_US |
dc.identifier.issn | 2151-464X | en_US |
dc.identifier.issn | 2151-4658 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/90249 | |
dc.description.abstract | Objective Classification criteria for systemic sclerosis (SSc; scleroderma) are being updated. Our objective was to select a set of items potentially useful for the classification of SSc using consensus procedures, including the Delphi and nominal group techniques (NGT). Methods Items were identified through 2 independent consensus exercises performed by the Scleroderma Clinical Trials Consortium and the European League Against Rheumatism Scleroderma Trials and Research Group. The first‐round items from both exercises were collated and redundancies were removed, leaving 168 items. A 3‐round Delphi exercise was performed using a 1–9 scale (where 1 = completely inappropriate and 9 = completely appropriate) and a consensus meeting using NGT was conducted. During the last Delphi round, the items were ranked on a 1–10 scale. Results In round 1, 106 experts rated the 168 items. Those with a median score of <4 were removed, resulting in a list of 102 items. In round 2, the items were again rated for appropriateness and subjected to a consensus meeting using NGT by European and North American SSc experts (n = 16), resulting in 23 items. In round 3, SSc experts (n = 26) then individually scored each of the 23 items in a last Delphi round using an appropriateness score ( 1–9 ) and ranking their 10 most appropriate items for the classification of SSc. Presence of skin thickening, SSc‐specific autoantibodies, abnormal nailfold capillary pattern, and Raynaud's phenomenon ranked highest in the final list that also included items indicating internal organ involvement. Conclusion The Delphi exercise and NGT resulted in a set of 23 items for the classification of SSc that will be assessed for their discriminative properties in a prospective study. | en_US |
dc.publisher | John Wiley & Sons, Inc. | en_US |
dc.title | Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Geriatrics | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan Scleroderma Program, Ann Arbor | en_US |
dc.contributor.affiliationum | University of Michigan Scleroderma Program, Division of Rheumatology/Department of Internal Medicine, 24 Frank Lloyd Wright Drive, Lobby M, Suite 2500, SPC 5753, PO Box 481, Ann Arbor, MI 48106 | en_US |
dc.contributor.affiliationother | Medical College of Wisconsin, Milwaukee | en_US |
dc.contributor.affiliationother | Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands | en_US |
dc.contributor.affiliationother | Toronto Western Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, Ontario, Canada | en_US |
dc.contributor.affiliationother | Maartenskliniek, Nijmegen, The Netherlands | en_US |
dc.contributor.affiliationother | McGill University, Jewish General Hospital, Montreal, Quebec, Canada | en_US |
dc.contributor.affiliationother | Université Paris Descartes, Hôpital Cochin, AP‐HP, Paris, France | en_US |
dc.contributor.affiliationother | Hospital Universitario 12 de Octubre, Madrid, Spain | en_US |
dc.contributor.affiliationother | Medical School, University of Pécs, Pécs, Hungary | en_US |
dc.contributor.affiliationother | Royal Free Hospital, London, UK | en_US |
dc.contributor.affiliationother | University Hospital Zurich, Zurich, Switzerland | en_US |
dc.contributor.affiliationother | David Geffen School of Medicine, University of California, Los Angeles | en_US |
dc.contributor.affiliationother | Clinica Medica, Università Politecnica delle Marche, Ancona, Italy | en_US |
dc.contributor.affiliationother | University of Manchester, Manchester Academic Health Science Centre, Salford Royal NHS Foundation Trust, Salford, UK | en_US |
dc.contributor.affiliationother | Istanbul University, Istanbul, Turkey | en_US |
dc.contributor.affiliationother | University of Toledo, Toledo, Ohio | en_US |
dc.contributor.affiliationother | Medical University of Bialystok, Bialystok, Poland | en_US |
dc.contributor.affiliationother | University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania | en_US |
dc.contributor.affiliationother | Justus‐Liebig University Giessen, Giessen, and Kerckhoff‐Clinic Bad Nauheim, Bad Nauheim, Germany | en_US |
dc.contributor.affiliationother | Charité University Hospital Berlin and German Rheumatism Research Centre, Berlin, Germany | en_US |
dc.contributor.affiliationother | Second University of Naples, Naples, Italy | en_US |
dc.contributor.affiliationother | St. Vincent's University Hospital and The Conway Institute for Biomedical and Biomolecular Research, University College Dublin, Dublin, Ireland | en_US |
dc.contributor.affiliationother | University of Basel, Basel, Switzerland | en_US |
dc.contributor.affiliationother | Stanford University, Stanford, California | en_US |
dc.contributor.affiliationother | Denver Health and Hospital Authority, University of Colorado Hospital, Denver | en_US |
dc.contributor.affiliationother | Jefferson Institute of Molecular Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania | en_US |
dc.contributor.affiliationother | Boston University School of Medicine, Boston, Massachusetts | en_US |
dc.contributor.affiliationother | Scleroderma Research Consultants, Avon, Connecticut | en_US |
dc.contributor.affiliationother | Medical University of South Carolina, Charleston | en_US |
dc.contributor.affiliationother | Georgetown University School of Medicine, Washington, DC | en_US |
dc.contributor.affiliationother | Azienda Ospedaliero‐Universitaria Careggi, Denothe Centre, University of Florence, Florence, Italy | en_US |
dc.contributor.affiliationother | University of Western Ontario, St. Joseph's Health Care London, University of Western Ontario, Schulich School of Medicine & Dentistry, London, Ontario, Canada | en_US |
dc.contributor.affiliationother | Amgen, Thousand Oaks, California | en_US |
dc.identifier.pmid | 22052558 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/90249/1/20679_ftp.pdf | |
dc.identifier.doi | 10.1002/acr.20679 | en_US |
dc.identifier.source | Arthritis Care & Research | en_US |
dc.identifier.citedreference | Wollheim FA. Classification of systemic sclerosis: visions and reality. Rheumatology (Oxford) 2005; 44: 1212 – 6. | en_US |
dc.identifier.citedreference | Charles C, Clements P, Furst DE. Systemic sclerosis: hypothesis‐driven treatment strategies. Lancet 2006; 367: 1683 – 91. | en_US |
dc.identifier.citedreference | Coulter C, Canadian Scleroderma Research Group, Scleroderma Clinical Trials Consortium, Hudson M, Steele R, Baron M, et al. The development of updated criteria for systemic sclerosis (SSc) using Delphi technique and cluster and frequency analyses from a large SSc patient database [abstract]. Arthritis Rheum 2009; 60 Suppl: S652. | en_US |
dc.identifier.citedreference | Johnson SR, Fransen J, Khanna D, Baron M, van den Hoogen F, Medsger TA Jr, et al. Validation of potential classification criteria for systemic sclerosis. Arthritis Care Res (Hoboken) 2012; 64: 358 – 67. | en_US |
dc.identifier.citedreference | Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005; 35: 35 – 42. | en_US |
dc.identifier.citedreference | Cutolo M, Matucci CM. Nailfold capillaroscopy and classification criteria for systemic sclerosis. Clin Exp Rheumatol 2007; 25: 663 – 5. | en_US |
dc.identifier.citedreference | Baron M, Bell M, Bookman A, Buchignani M, Dunne J, Hudson M, et al. Office capillaroscopy in systemic sclerosis. Clin Rheumatol 2007; 26: 1268 – 74. | en_US |
dc.identifier.citedreference | Maricq HR, Harper FE, Khan MM, Tan EM, LeRoy EC. Microvascular abnormalities as possible predictors of disease subsets in Raynaud phenomenon and early connective tissue disease. Clin Exp Rheumatol 1983; 1: 195 – 205. | en_US |
dc.identifier.citedreference | Rodnan GP, Jablonska S, Medsger TA. Classification and nomenclature of progressive systemic sclerosis. Clin Rheum Dis 1979; 5: 5 – 13. | en_US |
dc.identifier.citedreference | Clements PJ. Systemic sclerosis (scleroderma) and related disorders: clinical aspects. Baillieres Best Pract Res Clin Rheumatol 2000; 14: 1 – 16. | en_US |
dc.identifier.citedreference | Merkel PA, Clements PJ, Reveille JD, Suarez‐Almazor ME, Valentini G, Furst DE. Current status of outcome measure development for clinical trials in systemic sclerosis: report from OMERACT 6. J Rheumatol 2003; 30: 1630 – 47. | en_US |
dc.identifier.citedreference | Wigley FM, Hummers L. Management: holistic approach to systemic sclerosis. Physician's approach. In: Clements PJ, Furst DE, editors. Systemic sclerosis. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 371 – 84. | en_US |
dc.identifier.citedreference | Sterz M, McCloskey D. Management: holistic approach to systemic sclerosis. Nurse's approach. In: Clements PJ, Furst DE, editors. Systemic sclerosis. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2004. p. 385 – 92. | en_US |
dc.identifier.citedreference | LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202 – 5. | en_US |
dc.identifier.citedreference | Lonzetti LS, Joyal F, Raynauld JP, Roussin A, Goulet JR, Rich E, et al. Updating the American College of Rheumatology preliminary classification criteria for systemic sclerosis: addition of severe nailfold capillaroscopy abnormalities markedly increases the sensitivity for limited scleroderma [letter]. Arthritis Rheum 2001; 44: 735 – 6. | en_US |
dc.identifier.citedreference | Nair R, Aggarwal R, Khanna D. Methods of formal consensus in classification/diagnostic criteria and guideline development. Semin Arthritis Rheum 2011; 41: 95 – 105. | en_US |
dc.identifier.citedreference | Mukerjee D, St George D, Coleiro B, Knight C, Denton CP, Davar J, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003; 62: 1088 – 93. | en_US |
dc.identifier.citedreference | Khanna D, Denton CP. Evidence‐based management of rapidly progressing systemic sclerosis. Best Pract Res Clin Rheumatol 2010; 24: 387 – 400. | en_US |
dc.identifier.citedreference | Steen VD, Lucas M, Fertig N, Medsger TA Jr. Pulmonary arterial hypertension and severe pulmonary fibrosis in systemic sclerosis patients with a nucleolar antibody. J Rheumatol 2007; 34: 2230 – 5. | en_US |
dc.identifier.citedreference | LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001; 28: 1573 – 6. | en_US |
dc.identifier.citedreference | Harper FE, Maricq HR, Turner RE, Lidman RW, LeRoy EC. A prospective study of Raynaud phenomenon and early connective tissue disease: a five‐year report. Am J Med 1982; 72: 883 – 8. | en_US |
dc.identifier.citedreference | Maricq HR, Weinberger AB, LeRoy EC. Early detection of scleroderma‐spectrum disorders by in vivo capillary microscopy: a prospective study of patients with Raynaud's phenomenon. J Rheumatol 1982; 9: 289 – 91. | en_US |
dc.identifier.citedreference | Koenig M, Joyal F, Fritzler MJ, Roussin A, Abrahamowicz M, Boire G, et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty‐year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 2008; 58: 3902 – 12. | en_US |
dc.identifier.citedreference | Hachulla E, Launay D. Diagnosis and classification of systemic sclerosis. Clin Rev Allergy Immunol 2011; 40: 78 – 83. | en_US |
dc.identifier.citedreference | Walker JG, Pope J, Baron M, Leclercq S, Hudson M, Taillefer S, et al. The development of systemic sclerosis classification criteria. Clin Rheumatol 2007; 26: 1401 – 9. | en_US |
dc.identifier.citedreference | Avouac J, Fransen J, Walker UA, Riccieri V, Smith V, Muller C, et al. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi consensus study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis 2011; 70: 476 – 81. | en_US |
dc.identifier.citedreference | Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581 – 90. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.